BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu X, Wan C, Gan Z, Liu R, Chen Y, Wang J, Gan L, Chen Y, Li Y, He B, Yu Y. TNBG-5602, a novel derivative of quinoxaline, inhibits liver cancer growth via upregulating peroxisome proliferator-activated receptor γ in vitro and in vivo. Journal of Pharmacy and Pharmacology 2019;71:1684-94. [DOI: 10.1111/jphp.13159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Li R, Zhou S, Gan Z, Wang L, Yu Y. The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats. Molecules 2022;27:2594. [PMID: 35458793 DOI: 10.3390/molecules27082594] [Reference Citation Analysis]
2 Zhang QY, Yu Y. Crystal structure of 9-methoxy-2,3,4,4 a ,5,6-hexahydro-1 H -pyrido [1′,2′:1,6]pyrazino[2,3- b ]quinoxaline, C 15 H 18 N 4 O. Zeitschrift für Kristallographie - New Crystal Structures 2022;0. [DOI: 10.1515/ncrs-2022-0012] [Reference Citation Analysis]
3 Sun X, Feng L, Sun C, Kang C. Synthesis of Quinoxaline Derivatives as Intermediates to Obtain Erdafitinib. Pharm Chem J 2021;55:951-3. [DOI: 10.1007/s11094-021-02521-x] [Reference Citation Analysis]
4 Dan YR, Gan LL, Yu Y. Crystal structure of 2-methoxy-4 b ,5,14,15-tetrahydro-6 H -isoquinolino[2′,1′:1,6] pyrazino[2,3- b ]quinoxaline, C 19 H 18 N 4 O. Zeitschrift für Kristallographie - New Crystal Structures 2021;236:595-7. [DOI: 10.1515/ncrs-2021-0008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gan L, Gan Z, Dan Y, Li Y, Zhang P, Chen S, Ye Z, Pan T, Wan C, Hu X, Yu Y. Tetrazanbigen Derivatives as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Partial Agonists: Design, Synthesis, Structure-Activity Relationship, and Anticancer Activities. J Med Chem 2021;64:1018-36. [PMID: 33423463 DOI: 10.1021/acs.jmedchem.0c01512] [Reference Citation Analysis]